Home › Modalities › Nucleic Acid
Nucleic Acid (16 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 1 | Approved | $1.76B | 7 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.79B | 5 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 3 | Phase 2 | $2.73B | 6 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | 9 | NDA Submitted | $3.39B | 10 |
| ELTX | Elicio Therapeutics | Oncology | 1 | Phase 2 | $42.7M | 6 |
| GERN | Geron | Oncology | 3 | Approved | $638M | 3 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 28 | Approved | $6.55B | 29 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 1 | Phase 2 | $237M | 12 |
| PEPG | PepGen | Neurology Rare | 1 | Phase 2 | $171M | 1 |
| PHIO | Phio Pharmaceuticals | Oncology | 4 | Phase 1 | $9.6M | 4 |
| PRQR | ProQR Therapeutics | MetabolicNeurology Rare | 7 | Phase 1 | $191M | 7 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 9 | Approved | $1.91B | 11 |
| STOK | Stoke Therapeutics | Neurology Rare | 2 | Phase 3 | $1.74B | 2 |
| HURA | TuHURA Biosciences | Oncology | 3 | Phase 3 | $104M | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 3 | Approved | $231M | 27 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 5 | Phase 2 | $665M | 5 |
No companies match.